

## Confirmed Speakers

### Opening lecture

#### Opening Lecture Synthetic and Medicinal Chemistry for Biologics (IL01)



Prof. Jeffrey BODE  
(ETH ZURICH, Zürich, Switzerland)

### EFMC Prizes

#### EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Industry Discovery and Characterization of Potent, Efficacious and Orally Available Antimalarial Plasmeprin X Inhibitors (PR02)



Dr Teresa DE HARO GARCIA  
(UCB, Braine l'Alleud, Belgium)

#### EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Academia Targeted Protein Degradation via Molecular Glues (PR01)



Dr Georg WINTER  
(RESEARCH CENTER FOR MOLECULAR MEDICINE OF THE AUSTRIAN ACADEMY OF SCIENCES,  
Vienna, Austria)

### Invited lectures

#### Synthesis of Fluorinated Molecules Using Modern Synthetic Tools (IL04)



Dr Tatiana BESSET  
(INSA OF ROUEN, Mont-Saint-Aignan, France)

#### MicroCycle: A Machine Learning Driven, Automated and Integrated Platform for Drug Discovery (IL03)



Dr Cara BROCKLEHURST  
(NOVARTIS, Basel, Switzerland)

#### Next Generation Design-Make-Test-Analysis-Cycles (IL14)



Dr Clara CHRIST  
(BAYER, Berlin, Germany)

#### Making Difficult-to-Make Molecules: Photochemistry as an Enabling Tool (IL25)



Dr Susannah COOTE  
(UNIVERSITY OF BATH, Bath, United Kingdom)

#### Will Chemputers Dream of Electric Drugs (IL23)

## Confirmed Speakers



Prof. Leroy CRONIN  
(UNIVERSITY OF GLASGOW, Glasgow, United Kingdom)

### **New Catalytic Approaches for Simplifying Complex Amine Synthesis (IL06)**



Prof. Darren J. DIXON  
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

### **Taking Molecular Glue Degraders to New Heights (IL24)**



Dr Etienne DONCKELE  
(MONTE ROSA THERAPEUTICS, Basel, Switzerland)

### **Making and Breaking of C-S Bonds Using Metal Catalysis (IL15)**



Dr Ivana FLEISCHER  
(UNIVERSITY OF TÜBINGEN, Tuebingen, Germany)

### **Genochemetic Diversification of Natural Products (IL13)**



Prof. Rebecca GOSS  
(UNIVERSITY OF ST ANDREWS, St Andrews, United Kingdom)

### **Chemical Probes and their Relevance for Drug Discovery Programs – Examples from the Endocannabinoid System (IL05)**



Dr Uwe GRETHER  
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

### **Novel Modes of Enzyme Inhibition (IL26)**



Dr Anders JOHANSSON  
(ASTRAZENECA, Mölndal, Sweden)

### **Multicomponent Alkene Cross-Coupling by Base Metal Catalysis (IL20)**



Dr Ming Joo KOH  
(NATIONAL UNIVERSITY OF SINGAPORE, Singapore, Singapore)

### **The beautiful simplicity of rearrangements – towards ideal reactions? (IL10) Chemistry Europe Speaker**



Prof. Nuno MAULIDE  
(UNIVERSITY OF VIENNA, Vienna, Austria)

### **From BRD4 to KRAS: 12 Years of Oncology Small Molecules (IL16)**

## Confirmed Speakers



Dr Darryl MCCONNELL  
(BOEHRINGER INGELHEIM, Vienna, Austria)

### Structure Based Identification of Novel Albumin Binders for Half-Life Extensions of Proteins and Peptides (IL11)



Dr Maria MÉNDEZ PÉREZ  
(SANOFI, Frankfurt, Germany)

### Innovation in Synthetic Fluorine Chemistry through Use of Flow (IL02)



Prof. Timothy NOËL  
(UNIVERSITY OF AMSTERDAM, Amsterdam, The Netherlands)

### Synthesis of Glycosylated Natural Products or Analogues of Biological Interest (IL17)



Dr Stéphanie NORSIKIAN  
(INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES, Gif-sur-Yvette, France)

### Phenotypic Screen to NLRP3 lead (IL12)



Dr Daniel OEHLRICH  
(JANSSEN RESEARCH AND DEVELOPMENT, Beerse, Belgium)

### Challenges and Opportunities in CNS Drug Discovery (IL07)



Dr Frauke POHLKE  
(ABBVIE, Ludwigshafen, Germany)

### Covalent Chemical Biology with Natural Products and Novel Synthetic Warheads (IL19)



Prof. Thomas POULSEN  
(AARHUS UNIVERSITY, Aarhus C, Denmark)

### Enabling Technologies to Drive the MSD Portfolio (IL08)



Dr Rebecca RUCK  
(MERCK, SHARP & DOHME, Rahway, United States)

### Empowering Organic Synthesis: From Unique Methods to Complex Natural Products (IL09)



Prof. David SARLAH  
(UNIVERSITY OF ILLINOIS, Urbana, United States)

### Novel, Reversible DCAF1 Ligands Expand the TPD-Toolbox (IL21)

## Confirmed Speakers



Dr Martin SCHRÖDER  
(NOVARTIS, Basel, Switzerland)



Dr Anna VULPETTI  
(NOVARTIS, Basel, Switzerland)

### Machine Learning to Accelerate Design-Make-Test Cycles (IL18)



Dr Marwin SEGLER  
(MICROSOFT RESEARCH, Cambridge, United Kingdom)

### Natural Product Synthesis Through the Lens of Informatics (IL27)



Prof. Ryan SHENVI  
(SCRIPPS RESEARCH, La Jolla, United States)

### Disrupting the YAP-TEAD Protein-Protein Interaction with Small Molecules - Discovery of Drug Candidate NVP-IAG933 (IL22)



Dr Nicolas SOLDERMANN  
(NOVARTIS, Basel, Switzerland)

## Oral Communications

### Development of Selective mTOR Inhibitors for the Treatment of Cancer and Neurological Disorders (OC05)



Dr Chiara BORSARI  
(UNIVERSITY OF MILAN, Milan, Italy)

### EFMC-YMCS 2022 Best Oral Communication (OC09) Epitope Identification Using In-Silico Approaches, a Case Study: Nanobodies Binding to MGlU5 Receptor



Ms Floriane ESHAK  
(UNIVERSITY PARIS CITÉ, Paris, France)

### Direct Access to Unnatural Drug-Like Molecules by Photocatalytic Late-Stage Functionalization (OC07)



Prof. Olga GARCIA MANCHENO  
(UNIVERSITY OF MÜNSTER, Münster, Germany)

### Isolation and Biological Activities of Natural Products and Analogues from the Adriatic Coral Eunicella Cavolini (OC02)

## Confirmed Speakers



Prof. Dean MARKOVIC  
(UNIVERSITY OF RIJEKA, Rijeka, Croatia)

### High-Throughput Protac Synthesis and Direct to Biology Assaying for Rapidly Evaluating Targeted Protein Degradation (OC04)



Dr Afjal MIAH  
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

### RSC Medicinal Chemistry Lectureship Time to Shine for Constrained Peptides in Medicinal Chemistry (OC11)



Prof. Christoph NITSCHKE  
(AUSTRALIAN NATIONAL UNIVERSITY, Canberra, Australia)

### Design and Optimization of High Performance KSPi ADCs With Increased Tumor Selectivity: Enhancing the Therapeutic Window by Legumain-Mediated ADC Activation (OC03)



Dr Anne-Sophie REBSTOCK  
(VINCERX, Monheim am Rhein, Germany)

### Discovery of Imidazo[1,2-a]Pyridine Carboxamide BAY 1165747, a Long-Acting Soluble Guanylate Cyclase Stimulator for Resistant Hypertension (OC06)



Dr Alexandros VAKALOPOULOS  
(BAYER, Wuppertal, Germany)

### Cocktails For 19F NMR Fragment Screening: From Theory to Applications Using Enamine's Stock Chemical Space (OC08)



Prof. Dmytro VOLOCHNYUK  
(ENAMINE LTD, Kyiv, Ukraine)

### First time disclosure Discovery of the clinical candidate BI 1810631 (Zongertinib), a Selective HER2 Inhibitor for the Treatment of HER2 Exon 20 Insertion Driven Tumors (OC10)



Dr Birgit WILDING  
(BOEHRINGER INGELHEIM, Vienna, Austria)

### Divergent Synthesis as an Emergent Tool for Drug Discovery (OC01)



Prof. Alexandros ZOGRAFOS  
(ARISTOTLE UNIVERSITY OF THESSALONIK, THESSALONIKI, Greece)